New drug trial aims to intercept psychosis before it starts
Disease control
Recruiting now
This study is testing a new drug, MT1988, to see if it can improve memory, thinking skills, and reduce early symptoms in young people (aged 17-30) who are at high risk for developing psychosis. Participants will take the drug or a placebo twice daily for 8 weeks while researchers…
Phase: PHASE1, PHASE2 • Sponsor: Monument Therapeutics Limited • Aim: Disease control
Last updated Apr 02, 2026 07:27 UTC